China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that it has received a USD 35 million payment from US-based Merck Sharp & Dohme Corp. (MSD), in accordance with the licensing agreement signed in July this year.
Under the agreement, MSD has obtained global development, manufacturing, and commercial rights to an undisclosed investigational antibody drug conjugate (ADC) from Kelun’s pipeline. The deal includes an upfront payment of USD 35 million, with MSD committed to making milestone payments totaling USD 901 million, plus net sales commissions.
Previous Collaboration
In May this year, MSD initially signed a deal with Kelun to take development and commercial rights to another ADC, later revealed in a press release in late July to be the TROP2-targeted SKB-264.-Fineline Info & Tech
